Andrea S Gershon1, Michael A Campitelli2, Ruth Croxford2, Matthew B Stanbrook3, Teresa To4, Ross Upshur5, Anne L Stephenson6, Thérèse A Stukel7. 1. Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada2Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada3Department of Medicine, University of Toronto, Toronto, Ontario, Canada4The Hospital for Sick Children. 2. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 3. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada3Department of Medicine, University of Toronto, Toronto, Ontario, Canada6University Health Network, Toronto, Ontario, Canada. 4. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada3Department of Medicine, University of Toronto, Toronto, Ontario, Canada4The Hospital for Sick Children, Toronto, Ontario, Canada. 5. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada3Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 6. Department of Medicine, University of Toronto, Toronto, Ontario, Canada7Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada. 7. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada5Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Abstract
IMPORTANCE: Chronic obstructive pulmonary disease (COPD), a manageable respiratory condition, is the third leading cause of death worldwide. Knowing which prescription medications are the most effective in improving health outcomes for people with COPD is essential to maximizing health outcomes. OBJECTIVE: To estimate the long-term benefits of combination long-acting β-agonists (LABAs) and inhaled corticosteroids compared with LABAs alone in a real-world setting. DESIGN, SETTING, AND PATIENTS: Population-based, longitudinal cohort study conducted in Ontario, Canada, from 2003 to 2011. All individuals aged 66 years or older who met a validated case definition of COPD on the basis of health administrative data were included. After propensity score matching, there were 8712 new users of LABA-inhaled corticosteroid combination therapy and 3160 new users of LABAs alone who were followed up for median times of 2.7 years and 2.5 years, respectively. EXPOSURES: Newly prescribed combination LABAs and inhaled corticosteroids or LABAs alone. MAIN OUTCOMES AND MEASURES: Composite outcome of death and COPD hospitalization. RESULTS: The main outcome was observed among 5594 new users of LABAs and inhaled corticosteroids (3174 deaths [36.4%]; 2420 COPD hospitalizations [27.8%]) and 2129 new users of LABAs alone (1179 deaths [37.3%]; 950 COPD hospitalizations [30.1%]). New use of LABAs and inhaled corticosteroids was associated with a modestly reduced risk of death or COPD hospitalization compared with new use of LABAs alone (difference in composite outcome at 5 years, -3.7%; 95% CI, -5.7% to -1.7%; hazard ratio [HR], 0.92; 95% CI, 0.88-0.96). The greatest difference was among COPD patients with a codiagnosis of asthma (difference in composite at 5 years, -6.5%; 95% CI, -10.3% to -2.7%; HR, 0.84; 95% CI, 0.77-0.91) and those who were not receiving inhaled long-acting anticholinergic medication (difference in composite at 5 years, -8.4%; 95% CI, -11.9% to -4.9%; HR, 0.79; 95% CI, 0.73-0.86). CONCLUSIONS AND RELEVANCE: Among older adults with COPD, particularly those with asthma and those not receiving a long-acting anticholinergic medication, newly prescribed LABA and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a significantly lower risk of the composite outcome of death or COPD hospitalization.
IMPORTANCE: Chronic obstructive pulmonary disease (COPD), a manageable respiratory condition, is the third leading cause of death worldwide. Knowing which prescription medications are the most effective in improving health outcomes for people with COPD is essential to maximizing health outcomes. OBJECTIVE: To estimate the long-term benefits of combination long-acting β-agonists (LABAs) and inhaled corticosteroids compared with LABAs alone in a real-world setting. DESIGN, SETTING, AND PATIENTS: Population-based, longitudinal cohort study conducted in Ontario, Canada, from 2003 to 2011. All individuals aged 66 years or older who met a validated case definition of COPD on the basis of health administrative data were included. After propensity score matching, there were 8712 new users of LABA-inhaled corticosteroid combination therapy and 3160 new users of LABAs alone who were followed up for median times of 2.7 years and 2.5 years, respectively. EXPOSURES: Newly prescribed combination LABAs and inhaled corticosteroids or LABAs alone. MAIN OUTCOMES AND MEASURES: Composite outcome of death and COPD hospitalization. RESULTS: The main outcome was observed among 5594 new users of LABAs and inhaled corticosteroids (3174 deaths [36.4%]; 2420 COPD hospitalizations [27.8%]) and 2129 new users of LABAs alone (1179 deaths [37.3%]; 950 COPD hospitalizations [30.1%]). New use of LABAs and inhaled corticosteroids was associated with a modestly reduced risk of death or COPD hospitalization compared with new use of LABAs alone (difference in composite outcome at 5 years, -3.7%; 95% CI, -5.7% to -1.7%; hazard ratio [HR], 0.92; 95% CI, 0.88-0.96). The greatest difference was among COPD patients with a codiagnosis of asthma (difference in composite at 5 years, -6.5%; 95% CI, -10.3% to -2.7%; HR, 0.84; 95% CI, 0.77-0.91) and those who were not receiving inhaled long-acting anticholinergic medication (difference in composite at 5 years, -8.4%; 95% CI, -11.9% to -4.9%; HR, 0.79; 95% CI, 0.73-0.86). CONCLUSIONS AND RELEVANCE: Among older adults with COPD, particularly those with asthma and those not receiving a long-acting anticholinergic medication, newly prescribed LABA and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a significantly lower risk of the composite outcome of death or COPD hospitalization.
Authors: Gwen S Skloot; Paula J Busse; Sidney S Braman; Elizabeth J Kovacs; Anne E Dixon; Carlos A Vaz Fragoso; Nicola Scichilone; Y S Prakash; Christina M Pabelick; Sameer K Mathur; Nicola A Hanania; Wendy C Moore; Peter G Gibson; Susan Zieman; Betina B Ragless Journal: Ann Am Thorac Soc Date: 2016-11
Authors: Jeffrey H Silber; Paul R Rosenbaum; Richard N Ross; Justin M Ludwig; Wei Wang; Bijan A Niknam; Alexander S Hill; Orit Even-Shoshan; Rachel R Kelz; Lee A Fleisher Journal: Health Serv Res Date: 2016-02-29 Impact factor: 3.402
Authors: Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong Journal: J Infect Dis Date: 2020-01-01 Impact factor: 5.226
Authors: Roberto Benzo; Kristin Vickers; Paul J Novotny; Sharon Tucker; Johanna Hoult; Pamela Neuenfeldt; John Connett; Kate Lorig; Charlene McEvoy Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405